Navigation Links
Law Offices of Howard G. Smith Announces 25 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Micrus Endovascular Corporation
Date:11/8/2007

BENSALEM, Pa., Nov. 8 /PRNewswire/ -- Law Offices of Howard G. Smith announces a December 3, 2007, deadline to move to be a lead plaintiff in the securities class action lawsuit filed on behalf of shareholders who purchased the common stock of Micrus Endovascular Corporation ("Micrus" or the "Company")(Nasdaq: MEND) between February 12, 2007 and September 17, 2007, inclusive (the "Class Period"). The shareholder lawsuit is pending in the United States District Court for the Southern District of Florida.

The Complaint alleges that defendants violated federal securities laws by issuing material misrepresentations to the market concerning the Company's business and prospects, thereby artificially inflating the price of Micrus securities.

No class has yet been certified in the above action. Until a class is certified, you are not represented by counsel unless you retain one. If you purchased Micrus shares between February 12, 2007 and September 17, 2007, you have certain rights, and have until December 3, 2007, to move for Lead Plaintiff status. To be a member of the class you need not take any action at this time, and you may retain counsel of your choice. If you wish to discuss this action or have any questions concerning this Notice or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215)638-4847, Toll-Free at (888)638-4847, by email to howardsmithlaw@hotmail.com or visit our website at http://www.howardsmithlaw.com.


'/>"/>
SOURCE Law Offices of Howard G. Smith
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Law Offices of Howard G. Smith Announces Class Action Lawsuit Against LCA-Vision Inc.
2. The Law Offices of John David Hart: Texas Man Sues Medtronic in Body-Snatching Case
3. Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Micrus Endovascular Corporation
4. Demonstration at Carlyle Group Offices Monday as Grassroots Caravan of Caregivers, Senior Advocates Arrives in D.C. to Speak Out for Improved Care, Staffing at Nations Largest Nursing Home Chain
5. Law Offices of Howard G. Smith Announces Class Action Lawsuit Against WellCare Health Plans, Inc.
6. Law Offices of Howard G. Smith Announces 14 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Care Investment Trust Inc.
7. Northern Fertility & Reproductive Associates Adds Two Local Infertility Specialists to Staff, Opens New Offices In Center City And Blue Bell
8. Excerpts from DNC Chairman Howard Deans Remarks at the National Baptist Convention
9. UT Southwestern researcher named Howard Hughes Medical Institute investigator
10. CVS Caremarks Howard McLure Elected New PCMA Board Chairman
11. Especially Yours and Paula Young Team up with Diahann Carroll and Jaclyn Smith in the Fight Against Breast Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...age are more than twice as likely to develop demen...the Sahlgrenska Academy. , The study has just be.... , "Anyone carrying a lot of fat around the mid... a heart attack or stroke," says Deborah Gustafson...they nevertheless manage to live beyond 70, they r...
(Date:11/23/2009)... of Agriculture (USDA) has awarded a two-year, $90... Minnesota to complete sequencing the genome of th...nding will be used by the Turkey Genome Sequencing...g next-generation sequencing platforms, assemble t...ns in the final genome sequence by use of a sophis...
(Date:11/23/2009)...lationHealthPrograms ,, LOVELAND,Ohio,Nov.23/P...stitute(PHII),anon-profit501(c)(3)organization,isp...ovedtheHealthcareTransparencyAccreditationProgram,...M),alife,health,andwellnesscompanybasedinFarmingto...tationsealforfiveofitsprograms. ,, ThomasW.Wils...
(Date:11/23/2009)...il to the diet could reduce the risk of osteoporos...s, according to a report to be published in the I... Public Health . , Mer Harvi and colleagues at t... studied the effect of diabetes on bone health and...y the onset of osteoporosis. The researchers studi...
(Date:11/23/2009)...re blacks die than whites, study finds , ... and co-existing health problems don,t explain why...ates than whites, U.S. researchers say. , In an...l rates than whites for nearly all cancers, includ...ariety factors, such as differences in health care...
Breaking Medicine News(10 mins):Health News:Turkey Genome Sequencing Consortium awarded $0.9 million from USDA 2Health News:Population Health Impact Institute Launches Healthcare Transparency Accreditation Program(TM) 2Health News:Population Health Impact Institute Launches Healthcare Transparency Accreditation Program(TM) 3Health News:Flaxseed oil and osteoporosis 2Health News:Weight May Not Drive Racial Disparities in Colon Cancer 2
... Embraces Cutting-Edge Patient Safety ...Hoana Medical, Inc. announced a,partnership with K...olulu,Hawai,i, to deliver cutting-edge vigilance t...e LifeBed(TM) Patient,Vigilance System (LifeBed) t...
...ef Robert Weiner Says Calls for,Privatization and ...reet,Giveaway Turning Guarantee to Gamble, WASHIN...ry August 14, ex-U.S. House Committee on Aging Chi...iveaway which would turn Social Security from a gu...
...Contest Developed Innovative Technology To ...ITTSBURGH, Aug. 13 A team of students from the Te...ity will ring The NASDAQ Stock,Market Opening Bell...mpetition, the annual business school contest know...
...nc. ("Assurant"),(NYSE: AIZ ), a premier provider...ucts and services, announced today that Jane Meyer...esources, and Allen Walker,has been appointed seni...nd Mr. Walker will continue to report to Assurant,...
...fault for treatment gaps affecting 1 in every 100 ...y News) -- About one in 100 American adults has ac...h epilepsy aren,t receiving adequate treatment, ac...ults in 19 states. , "Despite having recent seizu...
... might think they are saving significantly more by...ey most likely will be disappointed or could be t...to MSU research. , Professor Jerry Punch of the ...ished their study on over-the-counter hearing aids...
Other Medicine News:Health News:Hoana Medical, Inc. Partners With Kahala Nui to Improve Patient Safety 2Health News:Hoana Medical, Inc. Partners With Kahala Nui to Improve Patient Safety 3Health News:Hoana Medical, Inc. Partners With Kahala Nui to Improve Patient Safety 4Health News:Social Security's 73rd Anniversary 2Health News:Tepper School Start-Up to Ring Nasdaq Stock Market Opening Bell 2Health News:Tepper School Start-Up to Ring Nasdaq Stock Market Opening Bell 3Health News:Assurant Announces Two Executive Appointments 2Health News:Epilepsy Receiving Inadequate Attention 2Health News:Study finds not all hearing aids are created equal 2
(Date:11/23/2009)...,Texas,Nov.23/PRNewswire-FirstCall/-- LexiconPharm...top-linedatafromitsPhase2clinicalstudywith LX1031 ...me(IBS)willbepresentedatGASTRO2009inLondonthisweek...ementinIBSsymptoms,willbepresentedbyDr. PhilipM.Br...ment,onNovember25,2009at2:30pmlocaltimeatthesessio...
(Date:11/23/2009)...xas,Nov.23/PRNewswire-FirstCall/--WoundManagementT...owingproviderofspecialtymedicalproducts,announcedt...dacomprehensivemanagementbusinessupdatetoillustrat...Q32009salesincreased33.5%to$102,926vs.Q32008saleso...reasedto$3,327,892vs.Q32008shareholderequityof$(32...
(Date:11/23/2009)...CISCO,Calif.,Nov.23/PRNewswire-FirstCall/--Anesiva...andDr.DavidC.U,PrichardhaveagreedtojointheAnesivab...gerbetweenAnesivaandArcionTherapeutics.Completiono...keplaceatthepreviouslyannouncedAnesiva2009AnnualMe...a.m.PSTat400OysterPoint,Suite107A,SouthSanFrancisc...
Breaking Medicine Technology:Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009 2Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009 3Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 2Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 3Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 4Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 5Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 2Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 3FDA Approves Lamictal 28R 29XR 28TM 29 3B An Extended Release Once Daily New Generation Treatment for Epilepsy 47447 1FDA Approves Lamictal 28R 29XR 28TM 29 3B An Extended Release Once Daily New Generation Treatment for Epilepsy 47447 2FDA Approves Lamictal 28R 29XR 28TM 29 3B An Extended Release Once Daily New Generation Treatment for Epilepsy 47447 3FDA Approves Lamictal 28R 29XR 28TM 29 3B An Extended Release Once Daily New Generation Treatment for Epilepsy 47447 4FDA Approves Lamictal 28R 29XR 28TM 29 3B An Extended Release Once Daily New Generation Treatment for Epilepsy 47447 5FDA Approves Lamictal 28R 29XR 28TM 29 3B An Extended Release Once Daily New Generation Treatment for Epilepsy 47447 6For Patients With Irritable Bowel Syndrome 28IBS 29 iPhone to the Rescue 47442 1For Patients With Irritable Bowel Syndrome 28IBS 29 iPhone to the Rescue 47442 2For Patients With Irritable Bowel Syndrome 28IBS 29 iPhone to the Rescue 47442 3NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD 26 NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 12377 1NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD 26 NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 12377 2NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD 26 NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 12377 3NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD 26 NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 12377 4NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD 26 NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 12377 5NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD 26 NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 12377 6NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD 26 NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 12377 7NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD 26 NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 12377 8
...an Biosciences,Incorporated (Nasdaq: KOSN ) today...tanespimycin, the company,s lead Hsp90 inhibitor, ...(R) in patients with HER2-positive,metastatic brea...can,Society of Clinical Oncology (ASCO), being hel...une 3, 2008., Abstract 1027, titled, "Phase 2 tri...
... Review Data Tuesday, May 13 at 1:00 p.m. EDT ...A, Spain and MENLO PARK, Calif., May 13 /PRNewswir... announced positive six-month follow-up,data from ...safety and,efficacy of the Custom NX(R) drug eluti...s with coronary artery disease., The CUSTOM III c...
Other Medicine Technology:Kosan Announces Data Presentations at ASCO 2008 Annual Meeting 2Kosan Announces Data Presentations at ASCO 2008 Annual Meeting 3XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting 2XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting 3XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting 4
...6 mm tip is angled 90 degrees with 1 mm flattened ...ure extension tube (0.03 inch ID x 8 inch long), f...r dissecting pre-retinal and other vitreo-retinal ..., angled tip of 30 gauge cannula facilitates place...
Vitreoretinal Micro Cannula
Moist Air Humidifying Chambers
Eye Garter Shield Cover - white
Medicine Products: